Axplora, a global CDMO partner for complex small molecules and antibody-drug conjugates (ADCs), has announced a multi-million-euro investment to expand lyophilization (freeze-drying) capabilities at its Le Mans, France site. The expansion is designed to strengthen integrated ADC contract manufacturing services
Andelyn Biosciences, Inc. has been selected by the Drake Rayden Foundation to manufacture clinical-grade adeno-associated virus (AAV) using its AAV Curator® Platform for the treatment of Nonketotic Hyperglycinemia (NKH), a rare inherited metabolic disorder caused by mutations in the GLDC
BIOEMTECH has signed a strategic supply agreement with NorthStar Medical Radioisotopes to secure Actinium-225 (Ac-225) for use in preclinical studies conducted by its customers. The agreement is designed to provide consistent access to the alpha-emitting isotope used in the development
Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) has acquired 100% of the shares of Recipharm Israel Ltd., which operates a cGMP manufacturing site in Yavne, Israel, and simultaneously entered into a long-term strategic commercial collaboration with Recipharm. The transactions expand Scinai’s manufacturing
ProBioGen has introduced CMC Navigator™, a set of four defined CMC service models designed to support biopharmaceutical companies across key stages of protein Chemistry, Manufacturing and Controls (CMC) development. The framework is intended to help teams align scope, timelines, and
Terumo Corporation has completed its acquisition of a drug product plant and quality control laboratory operations from WuXi Biologics in Leverkusen, Germany. The transaction officially closed on September 30, 2025. The acquisition expands Terumo’s position in the contract development and
OneSource Specialty Pharma Limited has received approval from the Saudi Food and Drug Authority (SFDA) for its generic Ozempic® (semaglutide) in Saudi Arabia, enabling commercialisation in partnership with Hikma Pharmaceuticals PLC across the Middle East and North Africa (MENA) region.
Shilpa Medicare Limited (SML) has entered into a binding agreement with NXI Therapeutics AG, a Swiss-based company, to develop and manufacture a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. The collaboration marks a step in Shilpa’s expansion within
Ampersand Capital Partners has acquired Purna Pharmaceuticals, a provider of development and manufacturing services for liquid and semi-solid dosage forms serving pharmaceutical industry customers. The transaction marks the next phase of growth for Purna and expands Ampersand’s life sciences portfolio.
Altasciences has appointed Marie-Hélène Raigneau as Chief Executive Officer and named Chris Perkin to its Board of Directors, both effective February 24, 2026. The announcement follows a leadership transition that has been underway for the past 12 months. Perkin, who
